Over 1,000 Chemotherapy Protocols And Counting

Phase 3, randomized trial, multicenter ttrial ( THOR) FGFR-altered metastatic urothelial carcinoma whose disease progressed after one or two previous treatments that included an a

20 Nov

Non-Small Cell Lung Cancer

New Indication: Perioperative Durvalumab for NSCLC

A Phase III, double-blind, placebo-controlled, multicenter, international Study (AEGEAN) Resectable Stages IIA to IIIB Non-small Cell Lung Cancer Perioperative Durvalumab + Chemot

20 Nov

Mesothelioma

New Indication: Lenvatinib with Pembrolizumab in Pleural Mesothelioma

Single-arm, single-centre, phase 2 study (PEMMELA) Pleural mesothelioma, who progressed after chemotherapy Pembrolizumab + Lenvatinib (n=38)

20 Nov

Colorectal Cancer

New Indication: Sotorasib with Panitumumab in kRAS G12C Mutated Colorectal Cancer

Phase 3, multicenter, open-label, randomized, active-controlled trial (CODEBREAK 300) KRAS G12 C mutant metatatic colorectal cancer, were disease progression or recurrence after r

26 Nov

Melanoma

New Drug: Relatlimab and Nivolumab for Advanced Melanoma

Double-blind, randomized Phase II-III trial Untreated metastatic or unresectable melanoma Relatlimab and nivolumab vs nivolumab alone

26 Nov

Breast Cancer

New Reference: Pembrolizumab in Triple-Negative Breast Cancer

Randomized, double-blind, placebo-controlled trial (KEYNOTE-522) Previously untreated stage II or III triple-negative breast cancer Neoadjuvant/adjuvant pembrolizumab (n=784) or pl

26 Nov

Diffuse Large B Cell Lymphoma

New Indication: Polatuzumab in Untreated DLBCL

Double-blind Phase III trial Untreated intermediate-risk or high-risk DLBCL Polatuzumab-R-CHP vs R-CHOP

26 Nov

Non-Small Cell Lung Cancer

New Drug: Selpercatinib in RET-Fusion Positive NSCLC

Open-label phase 1–2 trial Previously platinum-based chemotherapy Advanced or metastatic RET fusion positive NSCLC pts who had been treated with platinum (phase I: 49 pts) and wh

26 Nov

Non-Small Cell Lung Cancer

New Indication: Adjuvant Pembrolizumab in NSCLC

Randomised, triple-blind, phase 3 trial Stage IB (tumours of ≥4 cm in diameter), II, or IIIA NSCLC Pembrolizumab 200 mg (590) or placebo (587) / 3 weeks-18 cycles

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries